---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Hec50co type II endometrial adenocarcinoma cell line
treatment : EGF
effect    : activating
hours     : 12

control   :
    - GSM521595 1
    - GSM521596 1
perturbed :
    - GSM521597 1
    - GSM521598 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Hec50co type II endometrial adenocarcinoma cell line
treatment : EGF
effect    : activating
hours     : 24

control   :
    - GSM521601 1
    - GSM521602 1
perturbed :
    - GSM521603 1
    - GSM521604 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Hec50co type II endometrial adenocarcinoma cell line
treatment : gefitinib
effect    : inhibiting
hours     : 12

control   :
    - GSM521595 1
    - GSM521596 1
perturbed :
    - GSM521599 1
    - GSM521600 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Hec50co type II endometrial adenocarcinoma cell line
treatment : gefitinib
effect    : inhibiting
hours     : 24

control   :
    - GSM521601 1
    - GSM521602 1
perturbed :
    - GSM521605 1
    - GSM521606 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Ishikawa H type I endometrial adenocarcinoma cell line
treatment : EGF
effect    : activating
hours     : 12

control   :
    - GSM521607 1
    - GSM521608 1
perturbed :
    - GSM521609 1
    - GSM521610 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Ishikawa H type I endometrial adenocarcinoma cell line
treatment : EGF
effect    : activating
hours     : 24

control   :
    - GSM521613 1
    - GSM521614 1
perturbed :
    - GSM521615 1
    - GSM521616 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Ishikawa H type I endometrial adenocarcinoma cell line
treatment : gefitinib
effect    : inhibiting
hours     : 12

control   :
    - GSM521607 1
    - GSM521608 1
perturbed :
    - GSM521611 1
    - GSM521612 1

---
accession : E-GEOD-20854
platform  : A-AFFY-44
pathway   : EGFR
cells     : Ishikawa H type I endometrial adenocarcinoma cell line
treatment : gefitinib
effect    : inhibiting
hours     : 24

control   :
    - GSM521613 1
    - GSM521614 1
perturbed :
    - GSM521617 1
    - GSM521618 1
...
